Home Page / Solution / Solution Detail

Transfection Reagent – Hieff Trans™ and PEI

Transfection reagents have become routine reagents for studying gene function in eukaryotic cells. Transfection reagents are widely used in gene function research, gene expression regulation, and mutation analysis, as well as gene therapy, cell therapy, protein production, and vaccine production.

For DNA transfection reagents and RNA transfection reagents, Yeasen has a strong R&D and production team, continuously optimizes formulas, improves production processes, and has launched a variety of products based on cationic liposomes and cationic polymers. Scientific research institutions and enterprises provide a full range of products, and the product line covers all fields involved in transfection reagents.

 

Product advantages

Selection guide

Some of the articles published using our products

Regard reading

 

Product advantages

  • High efficiency: suitable for transient transfection or stable transfection of cell lines.
  • Low toxicity: Transfected cells remain well-viable.
  • Wide adaptability: comprehensive coverage of common cells and difficult-to-transfect primary cells.
  • Easy to operate: suitable for medium in the presence of serum, without changing the medium before and after transfection.
  • Cost-effective: economical and practical, high transfection efficiency, low price.

 

Selection guide

The selection of transfection reagents needs to be comprehensively considered according to the experimental purpose and experimental content, such as the transfected substances, specific cells, and the convenience of operation. We have made the following distinctions for your reference.

1. DNA transfection reagents

A. DNA < 10 kb

Name

Nucleic acid

Cell type

Advantage

Cat#

Size

Hieff Trans™ Liposomal Transfection Reagent

DNA(< 10 kb)

Adherent cells

1. High transfection efficiency

2. Less dosage

40802ES02/03/08

0.5 mL/1 mL/5×1 mL

Hieff Trans™ Suspension Cell-Free Liposomal Transfection Reagent

DNA(< 10 kb)

Suspension cells

1. Specialized Transfection of Suspension Cells

2. Low toxicity

3. High transfection efficiency

40805ES02/03/08

0.5 mL/1 mL/5×1 mL

Hieff Trans™ Liposome Nucleic Acid Transfection Reagent is a versatile liposome transfection reagent, suitable for DNA, RNA, and oligonucleotide transfection, with high transfection efficiency for most eukaryotic cells. Its unique formula allows it to be added directly to the medium, and the presence of serum does not affect transfection efficiency, which reduces the damage to cells caused by serum removal. There is no need to remove the nucleic acid-Hieff Trans™ complex or replace it with a fresh medium after transfection, and it can also be removed after 4-6 hours.

Figure 1. Hieff Trans™  Transfection Reagent operation flow map

 

Hieff Trans™ is supplied in sterile liquid form. Generally, for 24-well plate transfection, about 1.5 μL each time, 1 mL Hieff Trans™  can do about 660 transfections; for a 6-well plate, about 6 μL each time, 1 mL Hieff Trans™  can do about 160 transfections.

 

 

 

B. DNA >10 kb

Name

Nucleic acid

Cell type

Advantage

Cat#

Size

Polyethylenimine Linear(PEI) MW40000(rapid lysis)

DNA(> 10 kb)

Adherent cells and suspension cells

1. High transfection efficiency

2. Less dosage

40816ES02/03/08

100 mg/1 g/5×1 g

PEI 40000 is a highly charged cationic polyme, r with a molecular weight of 40,000 that binds negatively charged nucleic acid molecules very easily, forming a complex and allowing the complex to enter cells. PEI 40000 is a transient transfection reagent with low cytotoxicity, high transfection efficiency, and high gene expression efficiency in cells such as HEK293 and CHO. It has been verified that the linear PEI transfection reagent is widely applicable to a variety of cell lines including HEK-293, HEK-293T, CHO-K1, COS-1, COS-7, NIH/3T3, Sf9, HepG2, and Hela cells. The transfection efficiency is as high as 80%~90%.


 

2. RNA transfection reagents

Name

Nucleic acid

Cell type

Advantage

Cat#

Size

Hieff Trans™ Liposomal Transfection Reagent

siRNA

Adherent cells

1. High transfection efficiency

2. Less dosage

40802ES02/03/08

0.5 mL/1 mL/5×1 mL

Hieff Trans™ in vitro siRNA/miRNA Transfection Reagent

siRNA、miRNA、pre-miRNA, mimic miRNA, antimiRNA

Adherent cells and suspension cells

1. Excellent gene silencing efficiency

2. Low siRNA concentration

3. Low cytotoxicity

40806ES02/03

0.5 mL/1 mL

Hieff Trans™ in vitro siRNA/miRNA Transfection Reagent

Hieff Trans™ in vitro siRNA/miRNA Transfection Reagent is a PEI transfection reagent developed for the transfection of siRNA into mammalian cells. Suitable for transfection of siRNA and miRNA.

This product can achieve over 90% expression efficiency of 1 nM siRNA in a wide range of cell lines, avoiding off-target effects. Suitable for transfection of a variety of cells, including Hela, MCF-7, HepG2, CHO, and other adherent cells; and difficult-to-transfect suspension cell lines, such as K562 or THP-1 cells, can achieve 80% silencing efficiency; Including some primary cells, primary human fibroblasts and primary human hepatocytes, etc., the silencing efficiency of 80% can be achieved.

 

3. DNA/RNA cotransfection reagent

Name

Nucleic acid

Cell type

Advantage

Cat#

Size

Hieff Trans™ Liposomal Transfection Reagent

DNA(< 10 kb), siRNA

Adherent cells

1. High transfection efficiency

2. Less dosage

40802ES02/03/08

0.5 mL/1 mL/5×1 mL

 

4. Transfection reagents for industrial production applications

Name

Scenarios (including but not limited to)

Cell type

Advantage

Cat#

Size

Polyethylenimine Linear(PEI) MW40000(rapid lysis)

Viral vectors and Protein & Antibody Production

CHO series and HEK-293 series

1. High transfection efficiency

2. Less dosage

40816ES02/03/08

100 mg/1 g/5×1 g

 

5. List of Validated Cell Lines

Name

Hieff Trans™ Liposomal Transfection Reagent /40802ES

Cell

293T

Calu 1

HEK293

HO1980

N2A

THP-1

293T(suspension)

Chok1

HEK293T

HUVEC

NCI-H1975

TS cell

293FT

COS-7

Hela

MCF10A

NIH-3T3

U-87

3T3

DF-1

Hep2C

MCF-7

Neuro-2a

Vero

A549

H1299

Hep3B

MDA-MB-231

PC-12

WEHI

BV-2

H520

Hepa1-6

MDA-MB-231-LM2-4175

Raw264.7

WRL-68

B50

HaCaT

HepG2

MDCK

SGC-7901

 

C2C12

HCT116

HK2

MEF

T47D

 

Name

Hieff Trans™ in vitro siRNA/miRNA Transfection Reagent /40806ES

Cell

A549

HepG2

MCF-7

THP-1

 

 

HEK293T

CaSki

RAW264.7

primary human fibroblasts

 

Hela

K562

SiHA

primary human stem cells

 

 

Name

Polyethylenimine Linear(PEI) MW40000(rapid lysis)/40816ES

Cell

COS-1

CHO-K1

HEK-293

HepG2

Sf9

 

COS-7

Hela

HEK-293T

NIH-3T3

 

 

 

Some of the articles published using our products

[1] Liu R, Yang J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022 Jan 3. (IF:55)

[2] Luo J, Yang Q, et al. TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile. Cell. 2022 Mar 17. (IF:41.582)

[3] Zhou J, Chen P, et al. Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Mol Ther. 2022 Jan 5. (IF:11.454)

[4] Chen S, Cao X, et al. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022 Jan 24. (IF:16.808)

[5] Gu C, Wang Y, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022 Jan 6. (IF:11.161)

[6] Zhang Y, Yu X, et al. Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. Clin Transl Med. 2022 Feb.(IF:11.492)

[7] Qin J, Cai Y, et al. Molecular mechanism of agonism and inverse agonism in ghrelin receptor. Nat Commun. 2022 Jan 13. (IF:14.9)

[8] Tang X, Deng Z, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022 Mar 8.(IF:11.161)

[9] Xie F, Su P, et al. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. Adv Mater. 2021 Oct 19. (IF:30.849)

[10] Liang Y, Lu Q, et al. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021 Sep 7.(IF:16.9)

[11] Fan Y, Wang J, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021 Feb 2.(IF:27.403)

[12] Dai L, Dai Y, et al. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin. Mol Cell. 2021 Jul 1.(IF:17.97)

[13] Zhang K, Wang A, et al. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Neuron. 2021 Jun 16.(IF:17.17)

[14] Li T, Chen X, et al. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice. Nat Commun. 2021 Jan 27.(IF:14.92)

[15] Yan F, Huang C, et al. Threonine ADP-Ribosylation of Ubiquitin by a Bacterial Effector Family Blocks Host Ubiquitination. Mol Cell. 2020 May 21.(IF:17.97)

[16] Sun X, Peng X, et al. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020 Jun 12.(IF:14.911)

[17] Yang X, Wang H, et al. Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation. Protein Cell. 2020 Dec.(IF:14.872)

[18] Zou Y, Wang A, et al. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc. 2018 Oct.(IF:13.490)

[19] Hao H, Hu S, et al. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017 Mar 28.(IF:29.69)

 

Regard reading

Linear PEI MW 40000, a more efficient transfection reagent

In Vitro Cell Transfection Reagent Product Selection Guide